HELLS and prostate carcinoma: Our data are consistent with several large-scale CRISPR screen-based studies that have also identified HELLS as a key mediator of PARPi sensitivity in various cell lines, including those from triple-negative breast cancer, ovarian cancer, and prostate cancer [66–68].